These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 26416247

  • 21. LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/β-Catenin Signaling.
    Wang X, Lu X, Geng Z, Yang G, Shi Y.
    J Cell Biochem; 2017 Dec; 118(12):4745-4752. PubMed ID: 28513866
    [Abstract] [Full Text] [Related]

  • 22. Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.
    Lee G, Kang YE, Oh C, Liu L, Jin Y, Lim MA, Won HR, Chang JW, Koo BS.
    Auris Nasus Larynx; 2020 Oct; 47(5):870-880. PubMed ID: 32381353
    [Abstract] [Full Text] [Related]

  • 23. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib.
    Wang N, Wen J, Ren W, Wu Y, Deng C.
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [Abstract] [Full Text] [Related]

  • 24. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY, Liu RT.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
    [Abstract] [Full Text] [Related]

  • 25. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl‑1 pathway.
    Qu N, Hu JQ, Liu L, Zhang TT, Sun GH, Shi RL, Ji QH.
    Int J Oncol; 2017 May; 50(5):1683-1692. PubMed ID: 28393212
    [Abstract] [Full Text] [Related]

  • 26. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C, Gao Y, Wang C, Yu X, Zhang W, Guan H, Shan Z, Teng W.
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [Abstract] [Full Text] [Related]

  • 27. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.
    Campennì A, Ruggeri RM, Giuffrè G, Siracusa M, Alibrandi A, Cardile D, La Torre F, Lanzafame H, Giacoppo G, Ieni A, Trimarchi F, Tuccari G, Baldari S.
    Nucl Med Commun; 2021 Jun 01; 42(6):611-618. PubMed ID: 33625185
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ, Zarnegar R.
    Ann Surg Oncol; 2012 Mar 01; 19(3):973-80. PubMed ID: 21879273
    [Abstract] [Full Text] [Related]

  • 31. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients.
    Zhang J, Cai H, Sun L, Zhan P, Chen M, Zhang F, Ran Y, Wan J.
    J Exp Clin Cancer Res; 2018 Sep 12; 37(1):225. PubMed ID: 30208924
    [Abstract] [Full Text] [Related]

  • 32. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F, Gnemmi V, Devos P, Aubert S, Crépin M, Coppin L, Ramdane N, Bouchindhomme B, d'Herbomez M, Van Seuningen I, Do Cao C, Pattou F, Carnaille B, Pigny P, Wémeau JL, Leteurtre E.
    Thyroid; 2014 Sep 12; 24(9):1375-84. PubMed ID: 25012490
    [Abstract] [Full Text] [Related]

  • 33. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
    Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, Maciejewski A, Zebracka-Gala J, Lange D, Oczko-Wojciechowska M, Handkiewicz-Junak D, Jarzab B.
    PLoS One; 2015 Sep 12; 10(7):e0132821. PubMed ID: 26177218
    [Abstract] [Full Text] [Related]

  • 34. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
    Jiang XL, Zhang H, Chen YL, Peng L.
    Zhonghua Bing Li Xue Za Zhi; 2017 Mar 08; 46(3):160-165. PubMed ID: 28297755
    [Abstract] [Full Text] [Related]

  • 35. miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6.
    Wen Q, Zhao J, Bai L, Wang T, Zhang H, Ma Q.
    Oncol Rep; 2015 Oct 08; 34(4):2202-10. PubMed ID: 26239517
    [Abstract] [Full Text] [Related]

  • 36. Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer.
    Park HS, Jung CK, Lee SH, Chae BJ, Lim DJ, Park WC, Song BJ, Kim JS, Jung SS, Bae JS.
    Cancer Sci; 2012 Feb 08; 103(2):305-9. PubMed ID: 22118425
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.
    Biomed Pharmacother; 2014 May 08; 68(4):413-7. PubMed ID: 24721322
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.